Mesoblast Limited (MESO)
Mesoblast Limited, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
$14.55+0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-4.1%
The outlook
Mesoblast Limited currently reads as leaning bearish based on below its 50- & 200-day averages, 21% of the way from its 52-week low to high, avg target +141% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range21% of the way from its 52-week low to high
Price targetAvg target +141% vs current price
Market cap
$1.89B
52-wk high
$21.50
52-wk low
$12.66
50-day avg
$14.92
200-day avg
$16.12
Trailing P/E
—